Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 7, 2012, Pages

  Chaudhari, Tejasvi ^a   McGuire, William ^b  

^a JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; SCAVENGER;

HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; META ANALYSIS; MORTALITY; NEWBORN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ALLOPURINOL; FREE RADICAL SCAVENGERS; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866469325     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006817.pub3     Document Type: Review

References (41)

1. Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Archives of Disease in Childhood Fetal & Neonatal Edition 2006;91:F163-5.
2. Kaandorp JJ, van Bel F, Veen S, Derks JB, Groenendaal F, Rijken M, et al. Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials. Archives of Disease in Childhood Fetal & Neonatal Edition 2012;97:F162-6.
3. Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatric Neurology 2007;36:17-24.
4. Kaandorp JJ, van Bel F, Veen S, Derks JB, Groenendaal F, Rijken M, et al. Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials. Archives of Disease in Childhood Fetal & Neonatal Edition 2012;97:F162-6.
5. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 1998;101:185-93.
6. Kaandorp JJ, Benders MJ, Rademaker CM, Torrance HL, Oudijk MA, de Haan TR, et al. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study. BMC Pregnancy and Childbirth 2010;10:8. [PUBMED: 20167117]
7. Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, et al. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics 2009;124:350-7. [PUBMED: 19564319]
8. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Annals of Pharmacotherapy 1993;27:337-43.
9. Beveridge CJ, Wilkinson AR. Sodium bicarbonate infusion during resuscitation of infants at birth. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004864.pub2]
10. Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, et al. Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics 2001;108:61-70.
11. Edwards AD, Azzopardi DV. Therapeutic hypothermia following perinatal asphyxia. Archives of Disease in Childhood Fetal & Neonatal Edition 2006;91:F127-31.
12. Evans DJ, Levene MI, Tsakmakis M. Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001240.pub2]
13. Gonzalez FF, Miller SP. Does perinatal asphyxia impair cognitive function without cerebral palsy?. Archives of Disease in Childhood Fetal & Neonatal Edition 2006;91:F454-9.
14. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
15. Hunt R, Osborn D. Dopamine for prevention of morbidity and mortality in term newborn infants with suspected perinatal asphyxia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003484]
16. Inder TE, Volpe JJ. Mechanisms of perinatal brain injury. Seminars in Neonatology 2000;5:3-16.
17. Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003311.pub2]
18. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. American Heart Journal 1991;121:20-4.
19. Kecskes Z, Healy G, Jensen A. Fluid restriction for term infants with hypoxic-ischaemic encephalopathy following perinatal asphyxia. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004337.pub2]
20. Kumar A, Edward N, White MI, Johnston PW, Catto GR. Allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996;312:173-4.
21. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Human Development 2010;86:329-38. [PUBMED: 20554402]
22. MacLennan A. A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. BMJ 1999;319:1054-9.
23. Marro PJ, Baumgart S, Delivoria-Papadopoulos M, Zirin S, Corcoran L, McGaurn SP, et al. Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Pediatric Research 1997;41:513-20.
24. McGaurn SP, Davis LE, Krawczeniuk MM, Murphy JD, Jacobs ML, Norwood WI, et al. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome. Pediatrics 1994;94:820-3.
25. McGuire W, Fowlie PW, Evans DJ. Naloxone for preventing morbidity and mortality in newborn infants of greater than 34 weeks' gestation with suspected perinatal asphyxia. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003955.pub2]
26. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacological Reviews 2006;58:87-114.
27. Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxic-ischemic brain damage with allopurinol. Pediatric Research 1990;27:332-6.
28. Palmer C, Smith MB, Williams GD. Allopurinol preserves cerebral energy metabolism during perinatal hypoxic-ischemic injury and reduces brain damage in a dose dependent manner. Journal of Cerebral Blood Flow and Metabolism 1991;11:S144-9.
29. Palmer C, Towfighi J, Roberts RL, Heitjan DF. Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatric Research 1993;33:405-11.
30. Perlman JM. Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clinical Therapeutics 2006;28:1353-65.
31. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
32. Robertson NJ, Tan S, Groenendaal F, van Bel F, Juul SE, Bennet L, et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?. The Journal of Pediatrics 2012;160:544-52. [PUBMED: 22325255]
33. Roth SC, Baudin J, Cady E, Johal K, Townsend JP, Wyatt JS, et al. Relation of deranged neonatal cerebral oxidative metabolism with neurodevelopmental outcome and head circumference at 4 years. Developmental Medicine and Child Neurology 1997;39:718-25.
34. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. Archives of Disease in Childhood 1976;33:696-705.
35. Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Annals of Thoracic Surgery 1995;59:1519-23.
36. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 1998;101:185-93.
37. van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Therapeutic Drug Monitor 2006;28:339-44.
38. Vannucci RC, Perlman JM. Current and potentially new management strategies for perinatal hypoxic-ischemic encephalopathy. Pediatrics 1997;100:1004-14.
39. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Annals of the Rheumatic Diseases 2001;60:981-3.
40. Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. Journal of Experimental Biology 2004;207:3221-312.
41. Chaudhari T, McGuire W. Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006817.pub2]